More stories

  • in

    China invites U.S. business leaders to Beijing as it tries to decipher Trump’s trade plans

    China courted the executives of major U.S. businesses at an annual conference this week — a sign of how Beijing seeks to offset trade pressures, rather than retaliate forcefully.
    Chinese attendees weren’t that focused on what can be done to respond to U.S. tariffs, Stephen Roach, senior fellow at Yale Law School’s Paul Tsai China Center, told CNBC.
    At this week’s conference, China was trying to send a message of “reassurance” — on how it plans to boost consumption and how the country is headed in a “modestly positive direction” relative to what is happening in the United States, said Scott Kennedy, senior advisor and trustee chair in Chinese business and economics at the Center for Strategic and International Studies.

    Attendees pose for a group photo before the opening ceremony of the China Development Forum 2025 at the Diaoyutai Guesthouse on March 23, 2025, in Beijing.
    China News Service | China News Service | Getty Images

    BEIJING — China courted the executives of major U.S. businesses at an annual conference this week in a sign of how Beijing seeks to offset trade pressures, rather than retaliate forcefully.
    China has long sought to attract foreign investment as a way to bolster growth, while tapping business interests for potential influence on the White House, particularly under U.S. President Donald Trump. The U.S. has twice increased tariffs across all Chinese goods since January, but Beijing has only announced targeted duties and restrictions on a handful of American companies.

    Conversation on the sidelines of the state-organized China Development Forum this week in Beijing reinforced a more conciliatory stance than official rhetoric this month about how China is prepared to fight “any type of war” with the United States.
    Chinese conference attendees weren’t that focused on what can be done to respond to U.S. tariffs, Stephen Roach, senior fellow at Yale Law School’s Paul Tsai China Center, told CNBC.
    “The questions I’ve been getting more [are], why is Trump doing this? What is he trying to achieve? What does he think it takes to really make America great?” Roach said. He has attended the event since the early 2000s.

    “My answer is this is an unprecedented period for America’s role in the world economy. We’re going back to a tariff regime that history tells us can be extremely destructive,” Roach said, adding he expects more policy uncertainty in the U.S. and around the world “for a long, long time.”
    U.S. stocks have swung in recent weeks as investors try to assess the economic impact of Trump’s changing plans for tariffs on major U.S. trading partners. U.S. Federal Reserve Chair Jerome Powell last week said tariffs could delay progress on lowering inflation in the U.S.

    A message of ‘reassurance’

    At this week’s conference, China was trying to send a message of “reassurance” — on how it plans to boost consumption and how the country is headed in a “modestly positive direction” relative to what is happening in the U.S., said Scott Kennedy, senior advisor and trustee chair in Chinese business and economics at the Center for Strategic and International Studies, a think tank based in Washington, D.C.
    If the U.S. imposes significantly large tariffs in early April, “then you go from managing costs and de-risking to possibly de-coupling,” Kennedy told CNBC. “And then that might mean the game is up. So I think the level of anxiety is pretty high. And that’s why China is trying to provide this message of reassurance.”
    The Trump administration has threatened a swath of new tariffs on major trading partners starting early April. China has increased its trade with Southeast Asian countries and the European Union, but the U.S. remains Beijing’s largest trading partner on a single-country basis.
    The China Development Forum ran Sunday and Monday. Apple CEO Tim Cook was among the executives who attended, but Tesla CEO Elon Musk was not.
    “The increased optimism this year compared to last year at the CDF has been just so heart warming,” Ken Griffin, CEO of hedge fund Citadel, said during an official panel at the forum.
    Trump “is committed to American companies having access to a global market,” Griffin said. “And the President is willing to use tariffs to seek to enforce this worldview.”

    First step toward Xi-Trump meeting?

    Also on Sunday, U.S. Republican Senator Steve Daines met Chinese Premier Li Qiang in Beijing — the first time a U.S. politician has visited China since Trump began his latest term in January.
    “This was the first step to an important next step, which will be a meeting between President Xi and President Trump,” Daines told the Wall Street Journal. “When that occurs and where it occurs is to be determined.”
    The White House did not immediately respond to a request for comment.
    Li urged cooperation and said no one can gain from a trade war, according to state media.
    FedEx CEO Raj Subramaniam, Boeing Senior Vice President Brendan Nelson, Cargill CEO Brian Sikes, Medtronic CEO Geoffrey Martha, Pfizer CEO Albert Bourla, Qualcomm CEO Cristiano Amon, UL Solutions CEO Jennifer Scanlon and U.S. China Business Council President Sean Stein were also present at Daines’ meeting with Li, according to a foreign media pool report.
    China, the world’s second-largest economy, remains a significant source of revenue for many multinational corporations, not to mention a major part of their supply chains.
    Despite its efforts to bolster international business ties, the country has warned of countermeasures on U.S. tariffs and taken incremental steps.
    Following U.S. sanctions on Chinese telecommunications giant Huawei during Trump’s first term as president, Beijing launched an unreliable entities list that restricts foreign business activity with China.
    China added Calvin Klein parent PVH and a few other U.S. companies to the list after this year’s tariff increases. On Monday, China also said it would soon reveal new measures that would give it a legal basis for countering foreign pressure.

    Economic factors

    For U.S. companies in China, the state of the economic recovery has also been an important factor for local business plans.
    Since late September, China has stepped up efforts to support the economy. Top policymakers earlier this month affirmed stimulus plans and a recent effort to encourage private-sector tech entrepreneurs in the wake of DeepSeek’s artificial intelligence breakthroughs.
    “This year, you feel a lot of positive momentum beginning in China. So I feel like recovery is underway,” Wendell P. Weeks, CEO of Corning, told CNBC.
    However, China’s economy has struggled with deflationary pressure and a real estate slump, weighing on regional growth prospects for international businesses.
    Even Beijing’s push to support high-tech manufacturing has so far only added an average 1.1 percentage points to gross domestic product growth in each of the last three years — not enough to offset the 1.7 percentage point drag from real estate during that time, according to Goldman Sachs estimates.
    “We will remain optimistic because the role of technology is important, I think more than ever,” Qualcomm’s Amon told CNBC. “I think technology is going to be part of economic growth.” More

  • in

    Morgan Stanley’s near-term rally call: CIO Mike Wilson sees beaten-up Mag 7 stocks as winners

    Morgan Stanley’s Mike Wilson sees a meaningful rotation back into U.S. stocks, and he sees one beaten-up group as a winner.
    “It started out with a low-quality rally, which is what we expect – meaning a short squeeze,” the firm’s chief investment officer told CNBC’s “Fast Money” on Monday. “Then, what we noticed is the revision factors on the Mag Seven are actually starting to stabilize a bit. So, the last couple of days though stocks have acted better, and that can take the index higher. How high? 5,900. So, we’re almost there.”

    The major indexes had a notable start to the week. The S&P 500 gained roughly 1.8% and closed at 5,767.57 — about 6% below its all-time high. Meanwhile, the Dow jumped almost 600 points while the Nasdaq Composite surged more than 2%.
    The “Magnificent Seven” had a big role in Monday’s rally. Its members include Apple, Nvidia, Meta Platforms, Amazon, Alphabet, Microsoft and Tesla. The electric vehicle maker registered its best daily performance since November.
    But Wilson, who’s also the firm’s chief U.S. equity strategist, suggests a narrow window for gains. He focused his Monday research note on the idea.
    “Stronger seasonals, lower rates and oversold momentum indicators support our call for a tradeable rally from ~5500,” he wrote. “A weaker dollar and stabilizing Mag 7 EPS [earnings per share] revisions can drive capital back to the US. Beyond the tactical rally, volatility will likely persist this year.”
    And, he won’t rule out new lows for the year.

    “Whatever rally we’re getting now, we think probably end up fading into earnings, into May and June,” he added. “Then, we’ll probably make a more durable low later in the year.”
    According to Wilson, the market weakness is mostly tied to fundamentals and technicals.

    ‘Nothing to do with tariffs’

    “The reason the markets are lower over the course of the last three or four months has nothing to do with tariffs,” said Wilson. “It’s mostly to do with the fact that earnings revisions have rolled over. The Fed stopped cutting rates. You had stricter enforcement on immigration. You have [Department of Government Efficiency]. All of those things are growth negative.”
    Wilson’s S&P 500 year-end target is 6,500, which implies a nearly 13% gain from Monday’s close.
    “Could we make a new high in the second half of the year as people look forward to 2026? Yeah,” Wilson said.

    Join us for the ultimate, exclusive, in-person, interactive event with Melissa Lee and the traders for “Fast Money” Live at the Nasdaq MarketSite in Times Square on Thursday, June 5th.

    Disclaimer More

  • in

    Berkshire Hathaway employee wins $1 million in Warren Buffett’s March Madness bracket challenge

    Cooper Flagg #2 of the Duke Blue Devils moves the ball against the Baylor Bears during the second round of the 2025 NCAA Men’s Basketball Tournament held at Lenovo Center on March 23, 2025 in Raleigh, North Carolina. 
    Grant Halverson | NCAA Photos | Getty Images

    For the first time in nearly 10 years, a Berkshire Hathaway employee claimed Warren Buffett’s $1 million grand prize for his company’s NCAA bracket contest.
    An anonymous employee from aviation training company FlightSafety International, a subsidiary of Buffett’s Berkshire, won the annual internal bracket contest after correctly calling 31 of the 32 games in the first round of the men’s basketball tournament dubbed March Madness, according to a statement.

    The 94-year-old Oracle of Omaha was finally able to give out the big prize after relaxing the rules multiple times since the competition’s inception in 2016. Originally, Buffett, a Creighton basketball fan, set out to award anyone who could perfectly predict the Sweet 16.
    Then, in 2024, after the $1 million jackpot remained unclaimed, participants were given the advantage of waiving the results of the eight games among the No.1 and No. 2 seeds. Still, nobody cracked the code.
    This year, the rules were changed again so anyone who picks the winners of at least 30 of the tournament’s 32 first-round games would be eligible to win the prize.
    In fact, 12 Berkshire employees guessed 31 of the 32 first-round games correctly. The $1 million prize went to the person from that group that picked 29 games consecutively before a loss. That winner went on to pick 44 of the 45 games correctly.
    The other 11 contestants are getting $100,000 each.

    Don’t miss these insights from CNBC PRO More

  • in

    Wells Fargo’s strong rebound rally continues. How we’re playing the move higher

    Wells Fargo shares rose again Monday amid fresh Wall Street research and a broader market gain. It is tempting to take profits on the Club stock, which has mounted a 10% rally since its lowest close of 2025 on March 10. However, Jim Cramer advised investors to hold on for a little longer. The analysts’ moves are not surprising since the stock, while working its way higher, was still roughly 9.5% below its record-high close of $81.42 per share on Feb. 6. The news Shares of Wells Fargo were up nearly 2.5% to start the new week as traders brushed off multiple price target cuts and, instead, focused on signals that the U.S. may avoid starting a full-blown trade war. One of the price target cuts came from Morgan Stanley, which took its Wells Fargo target to $79 per share from $86. That still represents roughly 9% upside to Friday’s close. While citing “higher uncertainty driven by trade policy and a slower economic growth outlook” for the move, the analysts on Monday reiterated their buy-equivalent rating. They pointed to a number of positive drivers for Wells Fargo once the 2018 Federal Reserve-imposed $1.95 trillion asset cap has been removed. “Where does Wells benefit when the asset cap is lifted? (1) Faster deposit growth, (2) faster earnings asset growth, (3) higher markets [net interest income], (4) higher trading revenues, (5) lower expenses, and (6) a halo effect across the whole organization as they will be able to pivot to growth initiatives,” the analysts wrote. WFC YTD mountain Wells Fargo (WFC) year-to-date performance Big picture The Fed asset cap and other regulatory penalties known as consent orders were levied against Wells Fargo due to a series of account scandals and other past misdeeds. Management has cleared five consent orders since the start of 2025. The timing of the cap’s removal remains uncertain, some media reports — albeit unconfirmed by the bank — have suggested that it could happen as early as this year. Dealing with those regulatory challenges comes during a turbulent year for bank stocks and the overall stock market due to President Donald Trump’s near-daily barrage of tariff threats. Fellow portfolio financial names BlackRock , Goldman Sachs , and Capital One have faced similar volatility. This marks a reversal from post-election gains on high hopes that another Trump administration would bring about a more lenient regulatory environment, along with a boost in dealmaking activity. Bottom line We’re glad to see the Monday boost in Wells Fargo stock and the run it has been on during the past couple of weeks. Still, investors shouldn’t jump the gun and make a sale just yet. We believe this financial name has much more upside ahead. Like Morgan Stanley, we see the asset cap removal as a key driver for the stock. This, coupled with a multi-year turnaround plan, were big reasons why we started a position in Wells Fargo to begin with. The cap removal will allow the bank to expand budding parts of its business mix such as investment banking, further diversifying the company’s revenue streams. Currently, Wells Fargo relies heavily on interest-based incomes, which are at the mercy of the Fed’s policy rate decisions. Wells Fargo’s operating losses would likely come down as well with the lifting of the asset cap because the bank has been spending billions on risk and control infrastructure to appease U.S. regulators. Last year, according to Bloomberg, Wells Fargo submitted a third-party review of its risk and control changes for Fed consideration. The report said a decision to remove the cap requires a vote by the full Fed board. Jeff Marks, the Investing Club’s director of portfolio analysis, said he wouldn’t be surprised if the cap were to be lifted in 2025. “They’re getting more and more consent orders closed,” he said during Monday’s Morning Meeting. “There’s a lot of momentum there.” (Jim Cramer’s Charitable Trust is long WFC, COF, BLK, GS. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.

    A pedestrian walks by Wells Fargo headquarters at 420 Montgomery Street on December 04, 2024 in San Francisco, California. 
    Justin Sullivan | Getty Images More

  • in

    How Europe can hurt Russia’s economy

    VLADIMIR PUTIN is getting ready for an early Christmas. In the hope of a swift normalisation of relations with America, the Kremlin has been asking Russian firms which sanctions they would like Uncle Sam to lift first. America, for its part, seems impatient to deliver the gifts. Last week Steve Witkoff, a White House envoy, said that sanctions relief would come after a ceasefire is agreed in Ukraine—in other words, possibly before a full peace deal is ready. Mr Witkoff expects such a breakthrough within a “couple of weeks”. More

  • in

    How investors can ready their portfolios for a recession: ‘You’re looking for balance,’ expert says

    Economic forecasters have raised the odds of a U.S. recession amid an escalating trade war.
    Investors shouldn’t act emotionally if trying to prepare their portfolios for a downturn.
    Fundamentals like asset allocation and diversification are generally the most important considerations, advisors said.

    Nitat Termmee | Moment | Getty Images

    The odds of a U.S. recession have risen amid an escalating trade war. But most investors should ignore the impulse to flee for safety by exiting the market, financial experts say.
    Instead, the best way to brace for an economic shock is by double-checking fundamentals like asset allocation and diversification, they said.

    “You’re looking for balance rather than casting your lot with any one economic outcome,” said Christine Benz, director of personal finance and retirement planning for Morningstar.

    The probability of an economic downturn rose to 36% in March from 23% in January, according to fund managers, strategists and analysts polled for a recent CNBC Fed Survey. A recent Deutsche Bank survey pegged the odds at almost 50-50.
    President Donald Trump hasn’t ruled out the possibility of a U.S. recession and earlier this month said the economy was in a “period of transition.”
    Recession isn’t assured, though, and economists generally agree the chances are relatively low.

    ‘Market timing is a bad idea’

    Trying to predict when and if a recession will happen is nearly impossible — and acting on such fear often leads to bad financial decisions, advisors said.

    “Market timing is a bad idea,” said Charlie Fitzgerald III, a certified financial planner based in Orlando, and a founding member of Moisand Fitzgerald Tamayo. Trying to predict market movements and exit before a decline is like “gambling, it’s flipping coins,” he said.
    When it comes to investing, your strategy should be like watching paint dry, he said: “It should be boring.”
    He often tells investors to focus on ensuring their portfolio is properly diversified instead of worrying about a recession.
    More from Personal Finance:Stock volatility poses an ‘opportunity’How tariffs fuel higher pricesThe ‘danger zone’ for retirees when stocks dip
    When the economy heads toward a recession, it’s natural for investors to worry about falling stock prices and the impact on their portfolio. But investors quite often make bad moves and guess poorly, experts say.
    Emotional behavior — selling stocks during market downturns and missing the rebounds — is a big reason investors underperform the broad market, experts said.
    The average stock investor earned 5.5 percentage points less than the S&P 500 in 2023, for example, according to DALBAR, which conducts an annual investor behavior study. Investors earned about 21% while the S&P 500 returned about 26%, DALBAR said.
    The story was similar in 2022: Investors lost 21% while the S&P 500 declined 18%, it found.
    Stocks have always recovered after bottoming out during recessions, Fitzgerald said. Missing those rebounds can be costly, he said.
    “I’d definitely urge people to tap on the brakes before making big shifts in anticipation of some market outcome,” Benz said.

    Check your asset allocation

    That said, the prospect of a recession is a good time for investors to revisit their portfolios and make small adjustments, if necessary, experts said.
    Advisors suggest investors examine their asset allocation to make sure it’s appropriate for their goals and timeline, and to rebalance if their allocations have gotten out of whack. They should be diversified among (and within) asset classes, experts said.
    A target-date fund or balanced fund held in a retirement account may be good options for investors who want to outsource asset allocation, diversification and rebalancing to a professional asset manager, Benz said.

    Young investors saving for retirement — and who are more than 20 years from reaching their investment timeline — should generally be 100% in stocks, Fitzgerald said.
    However, there is one exception: Investors who are also saving for a short-term need within three to five years, perhaps a down payment on a home, should not keep those funds in the stock market, Fitzgerald said. Put that money in a safer place like a money market fund, so you know it’ll be there when you need it, he said.

    Retirees and near-retirees may benefit from a less risky portfolio, experts said. An allocation of 60% stocks and 40% bonds and cash, or a 50/50 split are good starting points, Benz said.
    Retirees generally need to keep a chunk of their portfolio in stocks — the growth engine of a portfolio — to help their investments last through old age, advisors said. Bonds generally act as a ballast during recessions, typically rising when stocks are falling, they said.
    Retirees who rely on their investments for income should avoid withdrawing from stocks if they’re declining during a recession, advisors said. Doing so, especially within the first five or so years of retirement, raises the odds that a retiree will deplete their portfolio and outlive their savings, research shows. (This is called “sequence of returns” risk.)
    Retirees who don’t have a bucket of bonds and cash from which to pull during such times may benefit from preparing while the economy is still strong, Benz said.
    “If you have a portfolio constructed well enough, [a recession] will be uncomfortable and the waves will toss [the ship] around a little bit, but the ship isn’t going to sink,” Fitzgerald said. More

  • in

    Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer

    Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year.
    The trial results are among the pharmaceutical industry’s most critical of the year, as they will bring Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes. 
    The pill could potentially help broaden access for patients in the U.S. and internationally and alleviate the supply constraints that have plagued the injections on the market. 
    Orforglipron could also help Eli Lilly solidify its dominance in the booming weight loss drug market as a slate of other drugmakers race to join. 

    A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.
    Scott Olson | Getty Images

    Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market.
    Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The company has said it expects to unveil data from five studies in patients with Type 2 diabetes and two trials in people with obesity in 2025. 

    Analysts expect the pill to be as effective, safe and tolerable to take as Novo Nordisk’s semaglutide – the active ingredient in its popular but costly weight loss injection Wegovy and diabetes drug Ozempic. The trial results are among the pharmaceutical industry’s most critical and closely watched of the year, as they bring Eli Lilly’s drug one step closer to becoming a new, needle-free alternative for weight loss and diabetes. 
    “This could join a growing toolbox of medications for obesity, and it could be a game-changer,” said Dr. Eduardo Grunvald, medical director for UC San Diego’s Center for Advanced Weight Management.
    If it enters the market, orforglipron could help more patients access the treatments and alleviate the supply shortfalls of the injections on the market. The pill could also help Eli Lilly solidify its dominance in the growing segment as a slate of other drugmakers race to bring a product to the market.
    Offering the first oral version of a so-called GLP-1 could help Eli Lilly capture an even greater share of the market for that popular class of weight loss and diabetes drugs. Eli Lilly is currently about three years ahead of other drugmakers developing pills, including Pfizer, AstraZeneca, Roche, Structure Therapeutics and Viking Therapeutics, Guggenheim analyst Seamus Fernandez told CNBC.
    Some analysts expect the market for GLP-1s to be worth more than $150 billion annually by the early 2030s. Oral GLP-1s could grow to be worth $50 billion of that total, Fernandez said. 

    In a statement, Eli Lilly said it is “investigating orforglipron for the potential to bring a safe and effective treatment to people with these diseases who are looking for a convenient, oral option.”
    Eli Lilly’s pill works in a similar way to Wegovy, Ozempic, and Novo Nordisk’s diabetes pill Rybelsus, targeting a gut hormone called GLP-1 to suppress a person’s appetite and regulate blood sugar. 
    But unlike those three medications, Eli Lilly’s pill is not a peptide medication. That means it is absorbed more easily in the body and doesn’t require dietary restrictions like Rybelsus does. 
    It is unclear whether orforglipron will have a hefty list price similar to those of the injections, which cost roughly $1,000 per month, or whether it will help expand insurance coverage for obesity treatments. Medicare and many employer-based plans still don’t cover those drugs. But so-called small molecule pills will at least be easier for Eli Lilly to manufacture than injections. 
    In January, Eli Lilly CEO Dave Ricks said the pill could receive U.S. regulatory approval as soon as early 2026. The company also said in its annual report in February it recorded a nearly $550 million “pre-launch inventory” charge for oforglipron, meaning it is preparing to manufacture the drug even before its approval. 
    “That’s a good indicator that they are comfortable with what they’re seeing across the trials,” BMO Capital Markets analyst Evan Seigerman told CNBC.
    Eli Lilly has benefitted from the windfall from tirzepatide – the active ingredient in its weight loss injection Zepbound and diabetes shot Mounjaro –  which targets GLP-1 but also activates another gut hormone called GIP.
    Fueled by those treatments, Eli Lilly has become the largest global pharmaceutical and health-care company by market cap, with a market value of about $814 billion as of Monday. The company raked in more than $45 billion in revenue in 2024 alone, a significant share of which came from its portfolio of diabetes and obesity products.

    Who could benefit from the pill

    While injections will likely remain a popular option, a once-daily pill like Eli Lilly’s could be much easier for some patients to take and store. 
    “What we’re going to see over the next couple of years is that we’re moving away from one-size-fits-all products to more customized products that are more directly aligned to the profile of the patient,” Seigerman said.
    Patients can inject Zepbound and Wegovy under their skin with a click of a button, but must follow specific instructions, such as storing the shots at certain temperatures and injecting in a different spot each week. Meanwhile, Rybelsus must be taken in the morning on an empty stomach with no more than four ounces of plain water.

    Rebekah Carl injects herself with her weekly dose of Wegovy in New Columbia, Pennsylvania, U.S., November 13, 2023.
    Hannah Beier | Reuters

    Orforglipron does not have dietary restrictions, and will also offer an option for patients who could benefit from treatment but are afraid of needles. 
    Th pill could also tap into new markets in countries that don’t have the resources for the cold supply chains needed to store and administer GLP-1 injections, Guggenheim’s Fernandez said.
    People who lost weight on the injections and are tired of taking a shot every week could also be “good candidates” to switch to a pill and take them as maintenance doses, which are meant to be taken long term to prolong the effects of a drug, Seigerman added. Eli Lilly is studying orforglipron as a maintenance dose in patients who took tirzepatide throughout a phase three trial called SURMOUNT-5, with results expected in early 2026. 
    Still, some patients who don’t mind taking injections may continue their current treatment regimen, UCSD’s Grunvald noted. He said some people already take several pills for other conditions each day, so they may prefer to take an injection once a week “and forget about it rather than adding another pill.”
    Eli Lilly’s pill could also be more fit for people who are overweight or “modestly obese,” said Leerink Partners analyst David Risinger. Those who have a very high body mass index will “best be treated with injectables that offer greater efficacy,” Risinger said.
    While orforglipron is expected to be as good for weight loss as Wegovy, Zepbound, on average, is more effective at helping patients lose weight than Novo Nordisk’s injection, according to real-world data and a head-to-head trial on the drugs.

    Late-stage diabetes trials on orforglipron

    ACHIEVE-1 – Study of orforglipron in adults with Type 2 diabetes and inadequate control of blood sugar levels with diet and exercise 
    ACHIEVE-5 – Study of orforglipron in patients with Type 2 diabetes and inadequate control of blood sugar levels with insulin glargine, with or without the diabetes treatments Metformin and/or SGLT-2 Inhibitors
    ACHIEVE-J – Long-term safety study of orforglipron in patients with Type 2 diabetes
    ACHIEVE-3 – Study of orforglipron compared with semaglutide in participants with Type 2 diabetes inadequately controlled with Metformin
    ACHIEVE-4 – Study of orforglipron compared with insulin glargine in patients with Type 2 diabetes and obesity or overweight at increased cardiovascular risk
    ACHIEVE-2 – Study of orforglipron compared with dapagliflozin (prescription drug for diabetes and heart failure) in patients with Type 2 diabetes and inadequate control of blood sugar levels with Metformin

    A pill is a welcome alternative for patients like Willow Baillies, 29, who has been injecting herself with cheaper, compounded versions of Zepbound because her insurance does not cover the branded medication. 
    The Food and Drug Administration, in most cases, now bars compounding pharmacies from making those unapproved versions because it declared the Zepbound shortage over in December. 
    Baillies, a human resources specialist based in Milwaukee, Wisconsin, said a pill would “offer peace of mind because I don’t have to think much about taking it.” Currently, her injections require careful preparation, such as disinfecting her entire counter with alcohol pads. 
    Orforglipron’s entrance into the market could also help the weight loss drug market reach more patients in the primary care setting who are not currently receiving treatment but could benefit from it, Seigerman said. While some primary care doctors can and do prescribe GLP-1s, others are hesitant due to concerns about side effects and administration since they are injections.  
    He said the primary care part of the market is key for the weight loss drug market to hit Wall Street’s lofty forecasts.

    Accessibility, pricing and insurance 

    Still, Seigerman said he believes primary care providers who prescribe pills may still encounter issues with pricing and insurance coverage.
    He said he doesn’t expect orforglipron to cost significantly less than existing injections because pharmaceutical products are “typically priced by the value that they bring, regardless of the route of administration.” For example, Rybelsus costs about $997 a month before insurance, the same list price as Ozempic. 
    Risinger said he expects orforglipron to be priced at a slight discount to Zepbound, which means Eli Lilly’s pill could cost significantly less than Wegovy. 
    The list price of Wegovy – nearly $1,350 per month – is already around a 20% premium to Zepbound’s list price of just under $1,100 per month, he said. That means if the pill costs 10% to 15% less than Zepbound, it would be almost a 30% to 35% discount compared to Wegovy, according to Risinger. 
    But Risinger said he does not necessarily expect the pill to lead to better insurance coverage for obesity medications. He believes orforglipron will be covered by some plans like Zepbound is, but certain employers will likely still fear that some patients are only using obesity drugs for cosmetic purposes. Other employers are still balking at the high costs associated with covering those treatments. 
    Jill Skala, a teacher in western Pennsylvania, said she would “definitely consider” taking a pill if it was less expensive than Zepbound and had “equal efficacy or better.” Skala, 49 is currently taking Zepbound and also has a nine-month supply of compounded tirzepatide, which she expects to use until the end of the year. 
    “I would probably just stay with Zepbound if [the pill] wasn’t significantly less expensive, as long as Zepbound was still working for me,” Skala told CNBC.

    Trial data expectations 

    Fotografiabasica | E+ | Getty Images

    Several analysts said they expect Eli Lilly’s pill to be as effective or slightly less than injectable semaglutide, the active ingredient in Ozempic and Wegovy, in phase three trials. 
    In patients with obesity, that implies weight loss of around 13% to 15%, according to a February note from JPMorgan analyst Chris Schott. That is in line with or slightly below Wegovy’s 15% average weight loss in phase three trials.
    Eli Lilly’s phase two trial examined different doses of the pill in overweight or obese patients, with a highest dose of 45 milligrams. But the company is only giving doses of up to 36 milligrams in phase three trials on orforglipron. 
    Overweight or obese patients who took 36 milligrams of the pill once a day lost 13.5% of their body weight on average after 36 weeks in Eli Lilly’s phase two trial. That compares with an average weight loss of 2.3% for people who received a placebo.
    Eli Lilly expects weight loss in people with diabetes to be “significantly less” than patients with obesity who don’t have diabetes, the company’s Chief Scientific Officer Daniel Skovronsky said on an earnings call in February. That’s based on prior studies on orforglipron and other GLP-1 therapies, he noted. 
    Schott said weight loss among diabetes patients could come in between 6% to 8%. He also expects hemoglobin A1c – a blood test that measures the average blood sugar level over the past two to three months – to improve by 1.8 to 2.1 points. That would be in line with results seen in diabetes patients who took Ozempic. 
    In a phase two trial, orforglipron led to an HbA1c reduction of up to 2.1% at 26 weeks in adults with diabetes, compared to a decrease of 0.4% among those who took a placebo. 

    Late-stage obesity trials, other studies on orforglipron

    ATTAIN-J – Study of orforglipron in Japanese adults with obesity 
    ATTAIN-1 – Study of orforglipron in adults who have obesity or are overweight with weight-related comorbidities 
    ATTAIN-2 – Study of orforglipron in adults who have obesity or are overweight and have Type 2 diabetes
    ATTAIN-MAINTAIN – Study of orforglipron for the maintenance of body weight loss in patients who have obesity or are overweight with weight-related comorbidities 
    ATTAIN-OSA – Study of orforglipron in people with obstructive sleep apnea and who have obesity or are overweight

    However, how well patients tolerate Eli Lilly’s pill – specifically the rate of gastrointestinal side effects in the trial – will be the “key focus” of the phase three study results, according to Schott. It’s an issue top of mind for doctors, patients and investors because side effects such as nausea and vomiting are a significant reason why some people stop taking the injections.
    Schott said the bar for orforglipron is nausea rates of less than 25% and vomiting rates in the low double digits for diabetes patients. 
    He expects orforglipron to cause slightly worse rates of gastrointestinal side effects in patients with obesity. That could lead to “tolerability worse than Zepbound but closer to Wegovy,” Schott added.
    Orforglipron’s nausea and vomiting rates in the phase two trial were “meaningfully greater” than those among patients who took 2-milligram doses of semaglutide in a phase three trial, Leerink’s Risinger said. 
    But he expects patients to tolerate Eli Lilly’s pill better in phase three trials because they are longer in duration than the mid-stage studies and likely involve slower titration. That refers to how quickly patients start at a lower dose of a drug and ramp up to a higher target dose. 
    On safety, Schott said he expects a “very low probability” of any issues that could put the entire development program for orforglipron at risk. He also believes it is highly unlikely that there will be any concerns related to liver toxicity – an issue that derailed one of Pfizer’s experimental obesity pills. 

    What the pill means for competitors

    Positive data on the pill and a potential approval would be a boon to Eli Lilly, but could also be good news for other companies developing oral GLP-1s, according to some analysts. 
    Orforglipron’s success could “validate” that administering a GLP-1 orally is possible, BMO’s Seigerman said. 

    Other drugmakers developing obesity pills

    But Seigerman said it will also put pressure on smaller companies developing pills, such as Structure Therapeutics, to find a partner that can help them compete in the weight loss drug market with pharmaceutical behemoths like Eli Lilly. 
    Guggenheim’s Fernandez said disappointing data or any safety issues that come up with Eli Lilly’s pill will “raise the bar that investors are considering” for non-peptide oral GLP-1s. Poor results could negatively impact the perception of those drugs, he added. More

  • in

    South Korea’s Hyundai to announce $20 billion U.S. investment

    South Korean conglomerate Hyundai will announce a $20 billion investment in U.S. onshoring.
    The investment is expected to be announced Monday at the White House by President Donald Trump, Hyundai Chairman Euisun Chung and Louisiana Gov. Jeff Landry.
    A new steel plant in Louisiana, which is part of the investment, is set to hire roughly 1,500 employees and will produce next-generation steel that will be used by Hyundai’s two U.S. auto plants to manufacture electric vehicles.

    South Korean conglomerate Hyundai will announce a $20 billion investment in U.S. onshoring that includes a $5 billion steel plant in Louisiana, according to people familiar with the plans.
    The plant is set to hire roughly 1,500 employees and will produce next-generation steel that will be used by Hyundai’s two U.S. auto plants to manufacture electric vehicles. The investment is expected to be announced Monday at the White House by President Donald Trump, Hyundai Chairman Euisun Chung and Louisiana Gov. Jeff Landry.

    Hyundai’s announcement comes as major international conglomerates are racing to dodge tariffs and avoid a trade war ahead of Trump’s April 2 tariff deadline. Taiwan Semiconductor Manufacturing Co. and Japan’s SoftBank are among the major foreign players that have visited the White House in the last two months to announce big U.S. onshoring plans.
    Hyundai Motor CEO José Muñoz recently told Axios that the “the best way for [Hyundai] to navigate tariffs is to increase localization.”
    The South Korean company is a top seller of electric vehicles in the U.S., competing directly with Tesla. It already has two major automotive plants in the U.S., one in Alabama and the other in Georgia. Hyundai on Monday is also expected to announce the opening of a third automotive plant, also in Georgia.
    South Korea is also among the countries with which the U.S. carries a trade deficit. In early March, Trump singled out South Korea for applying high tariffs to U.S. exports, saying the Asian ally’s tariffs were four times higher than those of the United States.
    Seoul has disputed that imbalance. As of 2024, South Korea’s effective tariff rate on U.S. imports stood at 0.79% as the two countries have a free trade pact, according to the South Korean government.
    The White House didn’t immediately return request for comment on Monday’s announcement. Hyundai declined to comment.

    Don’t miss these insights from CNBC PRO More